Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference

Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2(V617F) mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Andrew, Liu, James, Pu, Jeffrey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182587/
https://www.ncbi.nlm.nih.gov/pubmed/37173704
http://dx.doi.org/10.1186/s13045-023-01446-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182587/
https://www.ncbi.nlm.nih.gov/pubmed/37173704
http://dx.doi.org/10.1186/s13045-023-01446-0

Ejemplares similares